Search clinical trials for: Matching placebo to Aliskiren

Total 2142 results

Novartis

Completed

Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients (ALIAS)

Essential Hypertension

France
Novartis

Completed

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Essential Hypertension

Germany, Spain, United States
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

Obesity

United States
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Hypertension

China
Novartis

Completed

A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension

Hypertension

United States, Argentina, Colombia, France, Germany, India, Spain
Novartis

Completed

Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise

Hypertension

Singapore, Hungary, Czech Republic, United Kingdom
Novartis

Completed

Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal (ASSERTIVE)

Hypertension

Brazil, Canada, Ecuador, Germany, Hungary, Korea, Republic of, Malaysia, Mexico, Panama, Philippines, Singapore, Slovakia, Spain, Turkey, United Kingdom, Venezuela
Novartis

Completed

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

Hypertension

Estonia, France, Iceland, India, Italy, Korea, Republic of, Lithuania, Spain, Venezuela
Novartis

Completed

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Hypertension

Slovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland
Boehringer Ingelheim

Not yet recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated

Healthy
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

Healthy

United States
Cerecin

Completed

Tricaprilin in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Cerecin

Completed

Tricaprilin In Age-Associated Memory Impairment

Age-Associated Memory Impairment

United States
Novartis Pharmaceuticals

Terminated

Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) (ALTITUDE)

Cardiovascular Disease | Type 2 Diabetes Mellitus

Spain, China, United States, Belgium, Colombia, South Africa, Italy, United Kingdom, Germany, Hungary, Japan, Taiwan, Turkey, Netherlands, Greece, Switzerland, Austria, France, Thailand, Argentina, Canada, Singapore, Lithuania, Sweden, ... and more
GlaxoSmithKline

Completed

A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)

Pain, Inflammatory

United Kingdom, Germany, Poland
Christiana Care Health Services

Completed

The Effect of Renin Inhibition on Nerve Function in Diabetes

Diabetes

United States
Novartis Pharmaceuticals
The Cleveland Clinic

Completed

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients (AQUARIUS)

Coronary Artery Disease (CAD) | Coronary Atherosclerosis

Italy, Spain, Hungary, Australia, United States, Belgium, Canada, Germany, France, Argentina, Poland
Cellceutix Corporation

Completed

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

Plaque Psoriasis

United States
Novartis Pharmaceuticals

Completed

Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure (ESCAPE-SHF)

Heart Failure

Russian Federation, Germany, Poland
Wake Forest University Health Sciences
Novartis Pharmaceuticals

Completed

Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction (Aliskiren)

Heart Failure

United States
Novartis Pharmaceuticals

Terminated

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

Diabetic Macular Edema

Denmark, United States
Vanderbilt University Medical Center

Completed

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

High Blood Pressure

United States
Novartis Pharmaceuticals

Completed

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure (ASTRONAUT)

Acute Decompensated Heart Failure | Congestive Heart Failure

Colombia, Czech Republic, India, Italy, Belgium, Turkey, Argentina, France, Germany, Israel, Spain, Canada, Taiwan, United States, Singapore, Russian Federation, Philippines, Slovakia, Sweden, Hungary, Finland, Poland, Romania, Brazil
Guangdong Hengrui Pharmaceutical Co., Ltd

Enrolling by invitation

A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough

Refractory Chronic Cough

China
Brigham and Women's Hospital
Novartis

Terminated

Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients

Kidney Failure, Chronic | Kidney Disease

United States
Merck Sharp & Dohme LLC

Completed

The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)

Hypertension
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI); Novartis; National Institute...

Terminated

The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis

Endothelial Dysfunction

United States
Novartis

Completed

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

Hypertension

United States
University Medical Center Groningen

Terminated

Safety and Efficacy Study of Add On Aliskiren in Patients With Heart Failure and Renal Impairment (ARIANA-CHF-RD)

Heart Failure | Kidney Failure

Netherlands
Novartis

Completed

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

Myocardial Infarction

United States, Argentina, Belgium, Canada, Colombia, Czech Republic, Denmark, Germany, Hungary, India, Israel, Italy, Korea, Republic of, Netherlands, Norway, Poland, Russian Federation, Slovakia, Spain, Sweden, Turkey, United Kingdom and more
Ohio State University
Novartis

Terminated

Aliskiren Effect on Aortic Plaque Progression (ALPINE)

Atherosclerosis

United States
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Beth Israel Deaconess Medical Center
Novartis Pharmaceuticals

Completed

The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes

Diabetes Type 2

United States
Kallyope Inc.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

Obesity | Type 2 Diabetes Mellitus (T2DM)

United States
Vitae Pharmaceuticals, Inc.
Brigham and Women's Hospital

Completed

Direct Renin Inhibition and the Kidney

Renal Function

United States
Chinese University of Hong Kong

Completed

Aliskiren for Immunoglobulin A (IgA) Nephropathy

IgA Nephropathy

Hong Kong
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Netherton Syndrome

Belgium, United Kingdom, Australia, Germany, China, Malaysia, United States, Japan, France, Israel, Bulgaria, Italy, Switzerland, Netherlands, Portugal
Novartis Pharmaceuticals

Terminated

Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension

Hypertension | Ankle Edema

Netherlands
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

Obesity

United States
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes

Obesity | Type 2 Diabetes Mellitus in Obese

United States
US Department of Veterans Affairs

Completed

Matching, Outcomes and Costs in Substance Abuse/Psychiatric Treatment

Dual Diagnosis

United States
National Taiwan University Hospital
Taipei Veterans General Hospital, Taiwan

Unknown

Add-on Aliskiren Treatment in Patients With Chronic Congestive Heart Failure

Congestive Heart Failure

Taiwan
Novartis Pharmaceuticals

Terminated

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (ARIA)

Non-diabetic Nephropathy

Netherlands
Hospital for Special Surgery, New York
New York Presbyterian Hospital

Recruiting

Early Versus Delayed Bathing of Orthopaedic Surgical Wounds (EVDB)

Surgical Wound | Post Operative Wound Infection

United States
Wayne State University
Novartis

Unknown

Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension (VDATH)

Hypertension

United States
Novartis

Completed

Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Essential Hypertension

Japan
Resverlogix Corp

Not yet recruiting

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic
Suzhou Kintor Pharmaceutical Inc,

Completed

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

Alopecia | Male Pattern Hair Loss

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Belgium, Czechia, Ukraine, Poland, Malaysia, Serbia, Bulgaria, Argentina, Lithuania, Slovakia, Russian Federation, Canada, United Kingdom, Latvia

Search clinical trials for: Matching placebo to Aliskiren

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations